ערך בספרים למניה: Cyclacel (CYCC)

The bps metric reflects the dynamics of net assets per share, with the value currently standing at 2.28. The Cyclacel Pharmaceuticals (CYCC) team brings together leading cancer biologists dedicated to the study of cell cycles. Transparent management effectively allocates the R&D budget. Strong patent positions regarding inhibitors provide a robust defense, although early-stage trials maintain high volatility.

Net asset value per share allows for the elimination of speculative overvaluation by measuring residual capital after all liabilities are settled. For Cyclacel Pharmaceuticals (CYCC), where funding inflows depend on FDA verdicts regarding molecular toxicity, the average book value per share serves as an indicator of financial survival, confirming the biotech's ability to maintain its asset base while ensuring full patient retention in clinical trials.